PD-1/PD-L1
Les inhibiteurs de PD-1/PD-L1 sont des inhibiteurs de points de contrôle immunitaires qui bloquent l'interaction entre la protéine de mort cellulaire programmée 1 (PD-1) sur les cellules T et son ligand PD-L1 sur les cellules cancéreuses. Cette interaction supprime normalement la réponse immunitaire et permet aux cellules cancéreuses d'échapper à la détection immunitaire. En inhibant PD-1/PD-L1, ces inhibiteurs renforcent la capacité du système immunitaire à reconnaître et à détruire les cellules cancéreuses, induisant l'apoptose et la régression tumorale. Les inhibiteurs de PD-1/PD-L1 sont essentiels dans la recherche en immunothérapie et dans le traitement du cancer. Chez CymitQuimica, nous offrons une gamme d'inhibiteurs de PD-1/PD-L1 de haute qualité pour soutenir vos recherches en immuno-oncologie, apoptose et thérapie contre le cancer.
182 produits trouvés pour "PD-1/PD-L1".
Filtrer par
Pourcentage de pureté
0
100
|
0
|
50
|
90
|
95
|
100
- Tri par prix ascendant
- Tri par prix descendant
- Puretés inférieures
- Puretés supérieures
- Livraison estimée la plus rapide
Penpulimab
CAS :Penpulimab is a monoclonal antibody targeting PD-1 with antitumor activity, used in studies of pancreatic cancer.Degré de pureté :96.8% (SEC-HPLC) - 96.8% (SEC-HPLC)Couleur et forme :Transparent LiquidMasse moléculaire :145.14 kDa (Predicted)Sintilimab
CAS :Sintilimab (IBI308), an IgG4 monoclonal antibody, blocks PD-1, enhancing T-cell anti-tumor response; treats Hodgkin's, lung, and esophageal cancers.Degré de pureté :> 95% - >95.0% (SDS-PAGE); 95.0% (SEC-HPLC)Couleur et forme :LiquidMasse moléculaire :143.78 kDa (Predicted)Zimberelimab
CAS :Zimberelimab (GLS-010) is a humanized antibody targeting PD-1, with anticancer activity.Degré de pureté :95%Couleur et forme :Transparent LiquidMasse moléculaire :146.54 kDa (Predicted)AUNP-12 acetate
AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in additionFormule :C144H230N40O50Degré de pureté :95.07% - 99.29%Couleur et forme :White SolidMasse moléculaire :3321.61Durvalumab
CAS :Durvalumab is a humanized antibody for cancer, inhibiting PD-L1/PD-1 and CD80 interactions at very low concentrations.Degré de pureté :97.2% (SDS-PAGE); 95.3% (SEC-HPLC) - 97.7% (SDS-PAGE); 99.59% (SEC-HPLC)Couleur et forme :Transparent LiquidMasse moléculaire :146.03 kDa (Predicted)BMS-1001 hydrochloride
CAS :BMS-1001 hydrochloride is an orally active inhibitor of human PD-1/PD-L1 immune checkpoint with low-toxicity in cells.BMS-1001 alleviates the inhibitory effectFormule :C35H35ClN2O7Degré de pureté :97.36%Couleur et forme :SolidMasse moléculaire :631.115Budigalimab
CAS :Budigalimab (ABBV 181) is a humanized monoclonal antibody targeting PD-1 with potential antitumor activity.Degré de pureté :97% (SDS-PAGE); 98.8% (SEC-HPLC) - 97% (SDS-PAGE); 98.8% (SEC-HPLC)Couleur et forme :Transparent LiquidMasse moléculaire :145.72 kDa (Predicted)Dostarlimab
CAS :Dostarlimab (TSR-042) is an immune checkpoint inhibitor targeting PD-1, blocking its interaction with its ligands PD-L1 and PD-L2.Degré de pureté :>95%Couleur et forme :Transparent LiquidMasse moléculaire :144.18 kDa (Predicted)Tislelizumab
CAS :Tislelizumab, a PD-1 receptor monoclonal antibody, reduces Fcγ interaction and T cell clearance in advanced squamous NSCLC research.Degré de pureté :95.07%Couleur et forme :Transparent LiquidMasse moléculaire :145 kDa (Predicted)Ezabenlimab
CAS :Ezabenlimab (BI-754091) is an anti-PD-1 mAb, Kd 6 nM, blocks PD-1/PD-Ls, boosts T-cell IFN-γ, inhibits tumors in vivo.Degré de pureté :99.1% (SDS-PAGE); 96.9% (SEC-HPLC) - 99.1% (SDS-PAGE); 96.9% (SEC-HPLC)Couleur et forme :Transparent LiquidMasse moléculaire :145.21 kDa (Predicted)Spartalizumab
CAS :"Spartalizumab (PDR001), a humanized IgG4 monoclonal antibody, targets PD-1 to inhibit PD-L1/L2 interactions, useful in ATC research."Degré de pureté :SDS-PAGE:95.2%;SEC-HPLC:96.3%Couleur et forme :Transparent LiquidMasse moléculaire :145.74 kDa (Predicted)Garivulimab
CAS :Garivulimab (BGB-A333) is a humanized mAb targeting PD-L1 that enhances T-cell anti-tumor activity by blocking the PD-1/PD-L1 pathway.Degré de pureté :95%Couleur et forme :Transparent LiquidTPP-1 TFA
TPP-1 TFA is a high-affinity PD-L1 inhibitor (KD=95nM) that boosts T-cell function to curb tumor growth.Formule :C109H151F3N34O34S2Couleur et forme :SolidMasse moléculaire :2602.69Eciskafusp alfa
CAS :Eciskafusp alfa, a cis-targeted IL2v immunocytokine, acts on programmed cell death 1 (PDCD1, commonly known as PD-1), preferentially targeting antigen-specificDegré de pureté :98%Couleur et forme :SolidSotiburafusp alfa
CAS :Sotiburafusp alfa is a humanized bispecific fusion protein comprising a VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) connectedDegré de pureté :98%Couleur et forme :SolidPD-1/PD-L1-IN-52
PD-1/PD-L1-IN-52 (Compound Ⅲ-5) is an orally active inhibitor of PD-1/PD-L1 interaction, exhibiting an IC50 of 109.9 nM. It demonstrates antitumor activity in a C57BL/6 mouse model of MC38 colon carcinoma cells expressing human PD-1, achieving a tumor growth inhibition (TGI) rate of 49.6%.Couleur et forme :Odour SolidPD-1/PD-L1-IN-9
CAS :PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction.Formule :C22H24N2O2Degré de pureté :99.92%Couleur et forme :SolidMasse moléculaire :348.4382PD-1/PD-L1-IN-48
PD-1/PD-L1-IN-48 (compound HD10) is an effective inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 3.1 nM. It plays a vital role in cancer research.Couleur et forme :Odour SolidMS1-96
MS1-96 is an orally active PD-L1 (programmed death-ligand 1) degrader. It effectively reduces PD-L1 protein expression levels in various colorectal cancer (CRC) cell lines. The compound loses its ability to induce PD-L1 degradation upon HIP1R knockdown. MS1-96 binds directly to PD-L1 (KD= 2.58 μM) and enhances the interaction between HIP1R and PD-L1, altering PD-L1's intracellular transport in clathrin-coated vesicles. Additionally, MS1-96 induces abnormal N-glycosylation of PD-L1, leading to protein instability and accelerated lysosome-mediated degradation. MS1-96 is applicable for colorectal cancer research.HLX43
HLX43 is an ADC targeting PD-L1 with DAR=8 and a cleavable linker that releases C24, possessing both immune blockade and bystander killing effects.Degré de pureté :95% - 98.30% (SEC-HPLC)Masse moléculaire :153.06 kDa (Predicted)
